STUDY QUESTION: Do short-term and long-term exposures to low-dose folic acid supplementation alter DNA methylation in sperm?
Introduction
DNA methylation is an epigenetic modification in which a methyl group is added to the fifth position of the cytosine ring. Patterns of this specific epigenetic mark are initially acquired in male and female gametes (sperm and oocyte) and occur in~30 million CpG (5′-Cytosine-phosphate-Guanine-3′) dinucleotides in the human genome (Bird, 2002) . DNA methylation is involved in many biological events including genomic imprinting, transcriptional repression and X-inactivation. Proper maintenance of epigenetic patterns is paramount, with abnormal DNA methylation linked to developmental disorders and diseases such as cancer (Feinberg and Tycko, 2004) . As well, abnormalities in sperm DNA methylation patterns have been described in men suffering from infertility and associated with paternal age, with links to adverse outcomes in offspring (Houshdaran et al., 2007; Kobayashi et al., 2009; Hammoud et al., 2010 Hammoud et al., , 2011 Jenkins et al., 2014) .
The folate cycle plays a key role in DNA methylation, as it provides one-carbon methyl donors through the metabolism of folate originating from the diet. These one-carbon groups can then be used for the synthesis of nucleotide bases or shuttled towards remethylation of homocysteine to methionine; this essential amino acid is then activated to produce S-adenosyl methionine, the universal methyl donor (Crider et al., 2012) . The constant production of mature spermatozoa, through mitosis and meiosis during spermatogenesis, is a process with a high requirement for both nucleotides and methyl groups. In animal models, lower folate intake, together with disruptions in its metabolism, have detrimental effects on male reproduction, sperm epigenetic patterning and offspring outcome (Chan et al., 2010; Lambrot et al., 2013) . Similarly, human polymorphisms in several enzymes found within the folate metabolism pathway have been associated with male factor idiopathic infertility (Lee et al., 2006) .
In the USA and Canada, mandatory addition of folic acid to enriched grain products was implemented in the 1990s specifically to decrease the risk of neural tube defects (Centers for Disease and Prevention, 1992) . Post-fortification, serum folate concentrations increased at least 2-fold in the USA (Jacques et al., 1999; Centers for Disease and Prevention, 2008) . While there are benefits coming from an adequate supply of folic acid in the diet, little is known about potential adverse health effects of such supplements. There are three main folic acid intake sources: enriched cereal grain products, ready-to-eat cereals and supplements. A common dose of folic acid in supplements is 400 μg. Most individuals ingesting folic acid from all three folic acid intake sources, including a low-dose folic acid supplement containing ≤400 μg/day, do not exceed the tolerable upper intake level of folic acid for adults of 1000 μg/day (Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, 1998; Yang et al., 2010) . However, doses as high as 4-5 mg/day are recommended for women at high risk for neural tube defects (https://ods.od.nih.gov/factsheets/Folate-HealthProfessional; (Wilson et al., 2015) ), and men presenting with decreased sperm counts and idiopathic infertility are also treated with high-dose (5 mg/day) folic acid supplements (Wong et al., 2002; Ebisch et al., 2007) .
Based on the critical role of folate in one-carbon metabolism and cellular methylation reactions in particular, our goal was to ascertain the effect of a low-dose supplementation of folic acid (400 µg/day) on epigenetic patterns in sperm, in particular DNA methylation. Previously, we reported alterations in sperm DNA methylation patterns associated with the use of high-dose folic acid (5 mg/day) supplements in a group of infertile men (Aarabi et al., 2015) . Here, we used a unique group of sperm samples collected before 1998 when folic acid was added to the food supply. In this study, we assessed effects of 90 days of low-dose folic acid treatment on blood and seminal plasma folate levels and the sperm DNA methylome. In addition, we compared sperm DNA methylation patterns prior to and following mandatory folic acid fortification of enriched grain cereals to determine effects of long-term exposures to fortified foods.
Materials and Methods
Pre-fortification placebo and supplemented and post-fortification subjects Placebo and supplemented subjects were a subpopulation of individuals used in previously published studies (Wallock et al., 2001; Jacob et al., 2003) . Briefly, participants aged between 20 and 50 years were recruited from the San Francisco Bay area. Subjects were excluded from consideration if they consumed vitamin-mineral supplements within the past 6 months or had poor reproductive health. Blood and urine analyses were done to screen for general health indices and recreational drug use. Subjects in the intervention study were recruited to have low fruit and vegetable intakes (<3.5 servings/day). Qualified men were randomized in a double-blind fashion (investigator and subject) into either placebo or supplement group. The supplement and placebo were custom prepared and donated by Pharmavite Corp (Mission Hills, CA, USA). Supplements contained 272 mg ascorbic acid, 31 mg all-rac-α-tocopherol acetate and 400 μg folic acid, while the placebo tablets contained the vehicle used to prepare the supplement; thus the placebo tablets did not contain Vitamin C, Vitamin E or folic acid. Subjects were required to take the supplement or placebo daily for 90 days while continuing with their usual diet. A cohort of eight healthy non-smoking community control (or post-fortification cohort) subjects (age 18-32 years) was recruited through the McGill University Health Centre, Montreal as early as 2004. With mandatory folic acid fortification of grain products since November 1998 in Canada, participants in this cohort would have been exposed to the recommended daily folate intakes for several years.
Sample collection
Blood and semen collections from the intervention study were taken at the beginning (baseline) and the end of the 90-day supplementation period for the measurement of folate levels. After an overnight fast, blood was taken into evacuated tubes with EDTA (BD, Franklin Lakes, NJ, USA) and was centrifuged at 3000 g for 10 minutes at 4°C, and plasma removed and stored at −80°C for folate determination. Semen samples were collected through masturbation and were then allowed to liquefy at room temperature for 30 to 60 minutes. Samples were then centrifuged at 9400 g for 20 minutes at 4°C, and the supernatant (seminal plasma) was removed and stored at −80°C for folate assay. Cells were resuspended in 5 mM sodium phosphate-buffered 0.9% saline, pH 7.4 and stored at −80°C. Only semen was collected from the post-fortification cohort and was processed similarly for storage at −80°C.
Ethical approval
The study was approved by the US Department of Agriculture/ Agricultural Research Service, Human Studies Review Committee and the University of California, Berkeley, Committee for Protection of Human Subjects. The collection of samples was approved by the respective institutional ethics review board. Informed consent was obtained from all subjects from the different cohorts prior to study enrollment.
Blood and seminal plasma folate measurements
Plasma folate levels were measured as described in Wallock et al., (2001) . Briefly blood plasma folate was determined using a radioassay kit (Quantaphase B-12/Folate Radioassay; Biorad, Hercules, CA, USA), while seminal plasma folate levels were determined by microbiological assays using Lactobacillus rhamnosus (L. rhamnosus, ATCC 7469, Manassas, VA, USA).
DNA extractions
Semen samples were thawed on ice and were centrifuged at 4000 g for 5 min at 4°C. Supernatant was removed from the resulting sperm pellet and DNA was extracted from the sperm pellets using 1,4-dithiothreitol, Proteinase K and phenol:chloroform extraction methods as previously described (Chan et al., 2010) .
Quantitative methylation analysis of repeat regions
Genomic DNA was subjected to sodium bisulfite treatment using EpiTect Bisulfite Kit (Qiagen, Mississauga, ON, Canada) according to manufacturer's instructions. Quantitative methylation analysis of specific repeat regions was done using MassArray Epityper technology (Sequenom, San Diego, CA, USA) as previously described (Ehrich et al., 2005; McGraw et al., 2015) .
Restriction enzyme-based analysis of DNA methylation by restriction landmark genomic scanning A first genome-wide analysis of DNA methylation was done by restriction landmark genomic scanning (RLGS), capable of assessing methylation at 3000 loci in the human genome. RLGS assays were done as described (Okazaki et al., 1995; Chan et al., 2012; McGraw et al., 2015) .
DNA methylation profiling by MCIp and array hybridization
Differentially methylated regions (DMRs) between baseline and following 90 days of placebo or supplement interventions were detected by a combination of methyl-CpG immunoprecipitation (MCIp), followed by hybridization to human CpG island microarrays (Agilent technologies, Santa Clara, CA, USA). MCIp experiments were done as previously described (Gebhard et al., 2006; McGraw et al., 2015) . Signals with >0.7-fold enrichment were selected for further analysis. See Supplemental Information -(Methods) for further description of technique.
Array-based DNA methylation analysis
Genomic DNA was quantified with Qubit 2.0 Flurometer and Quant-iT TM dsDNA Assay kit (Invitrogen, Burlington, ON, Canada) and samples were sent to Genome Quebec for DNA methylation analysis using Infinium HumanMethylation450 BeadChip (450 K Array; Illumina, San Diego, CA, USA). Briefly, sodium bisulfite treatment of 500 ng of DNA was done as described above and hybridized on the array, following the Illumina HD Methylation protocol. Illumina HiScan fluorescent scanner was used for Chip analysis.
Statistical analyses
Statistical analyses were performed with GraphPad Prism (version 6.0; La Jolla, CA, USA) and R (www.cran.r-project.org). Blood and seminal plasma folate concentrations were analyzed using paired t-tests. For 450 k array data, to obtain methylation scores (β values) adjusted for technical artifacts in a percentile-specific and probe-type-specific way, data were normalized with funNorm (Fortin et al. 2014) . Paired t-tests comparing methylation before and after folic acid supplementation were done on logit-transformed β values, and two-group t-tests were done to compare changes between supplementation groups.
Results
Low-dose folic acid supplementation significantly increases blood and seminal plasma folate levels Sperm samples were collected between March 1996 and April 1997 prior to the beginning of mandatory national folic acid fortification program in January 1998. A subset of non-smoker samples (Table I) from 1996 (n = 9 and 10 for placebo and supplement, respectively) with plasma folate levels <10 nM was used because men who entered the study beginning in the first quarter of 1997 demonstrated increasing (>15 nM) plasma folate levels (Wallock et al., unpublished data) . By the end of the study in 1997, blood plasma folate levels had more than doubled (to~25 nM). Thus, by only including participants from 1996, although restricting the number of individuals we could study, we were able to control for potential early fortification efforts by excluding samples from men who entered the study in early 1997.
Subjects were given either placebo or a supplement containing 272 mg vitamin C, 31 mg vitamin E and 400 μg/day of folic acid for 90 days. Ninety days is the typical length of folic acid treatment given to infertile men and exposes a complete round of spermatogenesis covering all phases of male germ cell development including spermatogonia, meiotic spermatocytes, spermatids and mature spermatozoa. Blood and seminal plasma folate levels were determined in placebo and supplemented subjects at baseline and following 90 days of treatment to determine the effect of supplementation. At baseline, no differences were seen between the two groups of participants ( Fig. 1) . Following treatment, no discernible increase in mean plasma folate concentration was observed in the placebo group (blood plasma: 8.8 nM versus 9.5 nM; seminal plasma: 16.6 nM versus 15.5 nM). The fact that the placebo group experienced no significant change in folate levels between baseline and the end of the study (a 90-day period), further suggests that potential early folate fortification had no impact on this cohort. In contrast, individuals taking the folic acid supplements had significantly higher blood plasma folate (30.7 nM) and seminal plasma total folate (47.8 nM) compared to their baseline readings. Thus low-dose folic acid supplementation resulted in clear increases in both blood and seminal plasma folate concentrations.
Repeat region methylation remains unchanged following supplementation
As an initial measure of overall whole-genome levels of sperm DNA methylation, we assessed the methylation of repetitive elements, which are typically highly methylated and widely distributed across the genome. MassArray Epityper analysis was used to determine DNA methylation of different repeat regions, prior to and following treatment (Fig. 2) . This analysis by mass spectrometry allows for the analysis of several single and grouped CpGs in the regions of interest. Placebo and supplemented individuals showed similar sperm DNA methylation levels in repeat regions analyzed at baseline and following 90-day treatment, giving a first indication that low-dose folic acid supplements did not have major effects on repeat sequence methylation at the whole-genome level. Figure 1 Blood and seminal plasma folate levels were increased following folic acid supplementation. Blood plasma and seminal plasma folate levels were measured at baseline (filled bars) and following 90 days (open bars) of placebo or supplementation. While at baseline, no differences were observed between the two treatment groups, following the folic acid intervention a 3-fold increase in both blood and seminal plasma folate levels was seen. Mean (±SEM) ***P < 0.001.
RLGS and MCIp analysis of sperm DNA methylation following 90-day folic acid supplementation
To target a larger number of CpG sites across the genome, we next used different approaches to assess DNA methylation on a genomewide scale. An initial analysis of sperm DNA methylation was undertaken using RLGS. RLGS is a first-generation genome-wide DNA methylation analysis technique we have previously used to detect DNA methylation defects in rodent sperm associated with folate metabolic pathway enzyme defects and the use of cancer chemotherapy regimens (Chan et al., 2010 (Chan et al., , 2012 . When comparing baseline and 90-day time points within individual subjects, both placebo and supplemented subjects showed little evidence of intra-individual changes (Supplemental Figure S1B) ; an average of 7.3 changes were observed following treatments in both placebo and supplemented cohorts combined. This represents <1% of the~3000 loci interrogated by RLGS. Next, a second genome-wide DNA methylation assay that targets larger numbers of CpG sites was used in a subset of samples. Relatively CpG-rich regions of sperm DNA were targeted using MCIp with methyl-CpG binding domain protein 2 (MBD2) (Supplemental Figure S1C ). Even at the >0.7-fold enrichment cutoff, very few loci were found to be hyper-or hypomethylated following intervention with placebo or supplement, and differences in the magnitude (number of loci affected) of changes were not apparent between placebo and supplemented groups (Supplemental Figure S1C) . Together, the negative results of the RLGS and MCIp approaches indicated that a higher resolution genome-wide DNA analysis technique would be needed to pick up potentially subtle effects of folic acid supplements on the human sperm methylome. Greater detail of RLGS and MCIp techniques can be found in Supplemental Information-(Results).
Genome-wide analysis using 450 K arrays of sperm DNA methylation following short-term folic acid supplementation
To perform higher resolution genome-wide DNA methylation studies, we chose to use Illumina HumanMethylation450 Bead Arrays (450 K array), an approach that has previously detected infertility-and ageassociated alterations in the human sperm epigenome (Jenkins et al., 2014; Aston et al., 2015) . The 450 K array contains probes interrogating 485,764 cytosine positions in the human genome including CpG islands and other inter-and intragenic regions. Exclusion of several probes due to >90% similarity to multiple genomic location, to common single nucleotide polymorphisms within the entire probe sequences (minor allele frequency > 2/120), as well as exclusion of X and Y chromosomes, left 392,881 individual cytosine sites for further analysis. With linear regression analysis of the probe sets, high correlations (Pearson's coefficients, R 2 > 0.98) were observed with both inter-and intra-individual comparisons. Despite these high values, inter-individual regressions (Supplemental Figure S2A ) demonstrated greater spread of data points; regressions displayed a tighter distribution of β-values/methylation when examining a single subject at baseline versus 90-day treatment (Supplemental Figure S2B) . A probe-by-probe examination was conducted next, testing for changes in 90-day versus baseline samples within each treatment group, using paired t-tests. Manhattan plots shown in Supplemental Figure S3 plot the P-values for individual probes across the entire genome before and after treatment for placebo or supplement groups, respectively. A comparison of changes between these two treatment groups over time was assessed showing the changes between placebo and folic acid supplemented groups (Fig. 3A) . The top five probes with the smallest P-values for differences in the pre-post-treatment methylation changes between the two groups are listed in Fig. 3B ; however, none of these P-values met the necessary level of significance after correction for multiple comparisons (Bonferroni correction on the number of probes tested implies that a genome-wide significance of 5% would require a P < 1.27 × 10
−7
). The top five probes are found in genes encoding proteins with diverse roles including an aldehyde dehydrogenase implicated in the formation of GABA and associated with alcohol dependence (ALDH9A), an orphan receptor that helps regulate angiogenesis (ELTD1), a gene ortholog of C. elegans playing a role in axon formation (FEZ1), a MAP kinase involved in mitogen and stress response signaling (MAPKAPK3) and a member of the ligand gated ion channel family, which may play a role in nicotine dependence (CHRNA9 Yang et al., 2015) . A list of full gene names can be found in Supplemental  Table S1 .
Finally, equivalence testing was conducted to determine plausible ranges for average changes in methylation detectable given the sample size obtained. To this end, we constructed confidence intervals (CI) for differences in methylation changes between supplemented and placebo groups. This CI measured the difference in changes from baseline and 90 days following treatment, between the two cohorts. No significant changes were observed if the CI includes zero. Boundaries for the upper and lower CIs (Fig. 3C and D, respectively) were found to be small, encompassing −0.5 to +0.5 (on the logit beta scales), indicating that large differences between the two treatment groups are unlikely and inconsistent with the data.
With our relatively small sample size, we acknowledge that we were not able to rule out the existence of small changes that could become statistically significant in larger sample sizes. Nevertheless, as described in more detail in Supplemental Text -Methods (450 K Array Data Analysis and Power Calculations) and Discussion, we have not seen Figure 3 450 K array probe analysis and equivalence testing demonstrate no differences in DNA methylation between groups (n = 9 placebo, n = 10 supplemented) following 90-day treatments. (A) Negative log P-values were plotted along the entire chromosome following paired t-tests comparing differences in β-values observed between placebo and supplemented groups following 90-day intervention. (B) The top five probes/CpGs found to differ between groups are listed; however, significant changes were not observed following normalization and correction for multiple comparisons. The (C) upper and (D) lower confidence intervals following equivalence testing are depicted, which demonstrate that large differences between supplement and placebo subjects were unlikely.
changes that one might consider to be of a relevant size. Together, our overall analysis of the 450 K array data indicate that no significant changes in sperm DNA methylation could be found following administration of low-dose folic acid supplementation for 90 days.
Effects of folic acid supplementation on imprinted and other individual genes on the 450 K arrays
While the overall analysis of the 450 K data did not reveal effects of folic acid supplementation on the sperm DNA methylome, we wanted to more closely examine methylation of specific sequences previously shown to be affected by infertility, high-dose folic acid supplements or paternal age. Altered DNA methylation has been reported for imprinted genes in men with infertility (Marques et al., 2008; Kobayashi et al., 2009; Poplinski et al., 2010) . Therefore, we examined methylation found at DMRs of several imprinted loci found on the 450 K arrays. Normal high and low levels of sperm DNA methylation were observed through a heat map depicting the methylation of probes within DMRs of H19 and SNRPN, respectively (Fig. 4A) . We next assessed the average percent methylation across probe sets for paternally ( Fig. 4B ) and maternally ( Fig. 4C ) methylated imprinted genes, expected to be~100% and~0% methylated in sperm, respectively. No differences were observed between baseline and after 90-day treatments in either placebo or supplemented groups; >85% methylation was observed in all cases for H19 and DLK1-GTL2, while <10% methylation was seen for maternally methylated imprinted genes.
These results indicate that imprinted gene methylation was not perturbed following low-dose supplementation with folic acid. High-resolution genome-wide approaches such as the 450 K arrays and reduced representation bisulfite sequencing (RRBS) have recently been used to examine human sperm for effects of high-dose folic acid supplements, infertility, and paternal age. By RRBS high-dose folic acid supplements (5 mg/day for 6 months) resulted in altered sperm DNA methylation profiles, including those of genes involved in cancer and neurobehavioral disorders (Aarabi et al., 2015) . Nine of these high-dose folic acid responsive genes were examined in our 450 K data (Fig. 5) . While there were probes where methylation appeared altered (Fig. 5A) , the magnitude of change in actual β-value/methylation within each gene promoter was not significantly altered as illustrated in Fig. 5B . A similar approach was taken to examine genes found to have altered methylation in sperm due to infertility (Krausz et al., 2012) and paternal age (Jenkins et al., 2014) . Folic acid supplements in our study did not significantly affect methylation of the eight infertility-associated or the 48 paternal aging-associated gene promoters (Supplemental Figure S7) .
By 450 K array analysis sperm DNA methylation patterns appear to be relatively stable following years of folic acid fortification
The 90-day folic acid supplementation treatment was designed to cover one round of spermatogenesis in humans. Since the introduction of (imprinted maternally expressed transcript) and SNRPN (small nuclear ribonucleoprotein polypeptide N), demonstrating high and low levels of methylation across the regions, respectively. The average percent methylation of the probes within (B) paternally (H19; DLK1-GTL2, delta, Drosophila, homolog-like 1-gene trap locus 2) and (C) maternally methylated (SNRPN; PLAGL1, PLAG1 like zinc finger; MEST, mesoderm-specific transcript; KCNQ1OT1, KCNQ1 opposite strand/antisense transcript 1; PEG3, paternally expressed 3) imprinted genes demonstrates no differences in placebo and supplement groups at baseline, or following treatments. Mean ± SEM.
fortification of grain products in North America in 1998 and the use of folic acid supplements, men have been exposed to higher dietary folic acid levels, resulting in a doubling of plasma folate levels, in the postfortification era. Therefore, a T-statistic was performed in which placebo and supplemented groups collected in the 1990s were compared to the post-fortification cohort collected after 2004 (Table I) to examine the effect of long-term exposures. Fig. 6 depicts a scatterplot for placebo versus post-fortification and supplement versus postfortification. Although variability was observed, there was no dramatic deviation from the diagonal nor clear outliers found. This suggests that even following several years of exposure to fortified grain products, no major differences in sperm DNA methylation can be found when compared to pre-fortification samples. We also assessed methylation of individual sequences in sperm from our 19 pre-fortification men (placebo and supplemented individuals at baseline, time 0) as compared to the 8 men in the post-fortification group. None of the sequences found to be altered in previous studies of high-dose folic acid, infertility or paternal aging showed significantly different β-values/methylation in post-fortification as compared to pre-fortification groups (Supplementary Figure S8) .
Discussion
From animal and human studies, there is increasing concern that alterations to the sperm DNA methylome may be transmitted to the offspring (Tillo et al., 2016) . Folic acid supplements in particular have come under increased scrutiny with the safety of higher doses being questioned (Powers, 2007) . However, to date, even potential adverse effects on the sperm epigenome of commonly used low-dose folic acid supplements have not been tested. Here, we had access to a unique set of sperm samples from men sampled prior to food fortification with folic acid where we could assess effects of folic acid supplements on the sperm DNA methylome. Using genome-wide DNA methylation analysis techniques that have revealed sperm DNA methylation aberrations associated with advanced paternal age and male infertility, we found that exposures to 400 µg/day of folic acid for 3 months or long-term post-fortification era exposures did not alter DNA methylation patterns of male germ cells. Folic acid fortification was implemented in several countries worldwide to decrease the risk of neural tube defects. Indeed, studies have demonstrated a reduction in congenital abnormalities following the initiation of fortification (De Wals et al., 2007; Ionescu-Ittu et al., 2009) . However, it is still unclear if there are significant adverse health effects of such supplements. Early reports suggested an increased incidence of colorectal cancer and other detrimental effects associated with folic acid fortification and excessive exposures (Mason et al., 2007; Smith, 2007; Sie et al., 2011) . However, a recent large meta-analysis reported that supplementation did not lead to increased cancer risks in randomized folic acid trials (Vollset et al., 2013) . For male reproduction, high-dose folic acid is given to men presenting with idiopathic infertility and we recently demonstrated that men taking supplements containing high doses (5 mg/day) of folic acid for 6 months showed altered sperm DNA methylation that was exacerbated in those with a deficiency in methylenetetrahydrofolate reductase (MTHFR), a key enzyme involved in folate metabolism (Aarabi et al., 2015) . It was unclear from the latter study whether abnormal sperm DNA methylation patterns were related to infertility, high-dose folic acid or a combination of the two.
In this study, subjects with no history of infertility were given either placebo or supplements containing 400 μg of folic acid. Along with folic acid, vitamins E and C were also part of the supplement formulation but were not included in placebo tablets; these vitamins play roles as antioxidants and cofactors in enzymatic reactions. Previous results from the same cohort studied here showed no effects on oxidant markers following administration of these vitamins (Jacob et al., 2003) . Although no roles in DNA methylation have been linked to vitamin E, vitamin C has recently been shown to modulate the function of teneleven translocation enzymes, a family of enzymes with roles in the production of 5-hydroxymethylcytosine (5hmC) and DNA demethylation (Blaschke et al., 2013; Yin et al., 2013) . However, the absolute content of 5hmC is dynamic throughout the course of spermatogenesis, and its content relative to total cytosine or 5-methylcytosine is negligible (Gan et al., 2013) .
Blood and seminal plasma levels from all participants in the intervention study were determined at baseline and following the 90-day intervention with supplement. At the beginning of the study, mean blood plasma folate level was 9.6 nM for all participants. At this level, participants would be considered to have low or deficient plasma folate, when compared to the WHO determination, set at < 10 nM serum/ plasma folate (de Benoist, 2008) . A pre-selection of subjects for low fruit and vegetable intake would have most likely contributed to their low folate status. Following the 90-day treatment, folate levels increased 3-fold in participants receiving supplements, with no detectable change for the placebo group. Although there has been no standard determined, previous studies have shown that seminal plasma folate levels are at a concentration~1.5-fold greater than those found in blood (Landau et al., 1978; Wallock et al., 2001) ; a similar fold increase in baseline seminal plasma folate was observed in placebo versus supplemented subjects. Folate levels were not measured in the post-fortification cohort recruited in 2004; however, studies have demonstrated 2-fold increases in population plasma folate concentrations following food fortification (Jacques et al., 1999; Centers for Disease and Prevention, 2008) ; indeed baseline concentrations of serum folate levels in a recent Canadian study were similar to those measured in our analysis following 90-day low-dose folic acid supplementation (~30 nM) (Aarabi et al., 2015) .
Several complementary techniques were used to assess intraindividual variation of the 90-day treatment intervention on the sperm epigenome. Repetitive elements, make up approximately half of the mammalian genome and their silencing is important for genomic stability (Deininger and Batzer, 2002) ; silencing of these potentially active elements can be achieved through epigenetic regulation, such as methylation of DNA (Bourchis and Bestor, 2004) . MassArray Epityper was employed for the analysis of these regions and revealed no differences following supplementation. Genome-wide analysis of methylation using RLGS was able to semi-quantitatively analyze~3000 loci in the human methylome. Examination with MCIp followed by hybridization to CpG island arrays offers a 10-fold increase in the number of regions interrogated; however, this technique is not quantitative. The use of the MBD2 protein for immunoprecipitation targets more hypermethylated areas of the genome as well. The 450 K Array allowed for the investigation of methylation at the greatest number of sites as well as the interrogation of specific genes previously shown to have altered methylation in sperm associated with high-dose folic supplements, infertility or paternal age. Together, the negative results from these different genome-wide approaches indicate that the human sperm epigenome is apparently stable following exposure to low-dose folic acid supplementation. Few changes in methylation were found, and any differences observed between placebo and supplemented cohorts were not shown to be significant. Even following years of exposure to fortified foods, sperm DNA methylation patterns were indistinguishable β-values between the pre-fortification group (at baseline, n = 19, 9 from the placebo, 10 from the supplemented groups) and postfortification cohort (n = 8). A scatterplot of the t-statistic of placebo versus post-fortification (x-axis) and supplement versus postfortification (y-axis) subjects demonstrates no differences in sperm DNA methylation even following exposures to years of food supply fortification with folic acid.
between placebo or supplementation groups examined. Although there were no apparent differences in sperm DNA methylation profiles pre-and post-fortification, it should be noted that this study could not control for confounding factors for these comparisons. The wide range of techniques used in our study failed to detect significant changes to DNA methylation. We chose techniques similar to those that have revealed sperm DNA methylation abnormalities associated with infertility and paternal age (Jenkins et al., 2014) . However, it should be noted that genome-wide analyses used in previous sperm studies and here target mainly CpG dense regions such as CpG islands and promoter regions of genes; these are of interest due to their involvement in transcriptional regulation (Deaton and Bird, 2011) . These techniques, however, do not cover a large proportion of cisregulatory elements; data are accumulating that such sites can be altered in human diseases such as cancer. Analysis of these important elements would require determining the methylation state of all CpG dinucleotides throughout the genome using techniques such as high depth whole-genome bisulfite sequencing (i.e. MethylC-Seq).
Higher folic acid doses than the one used in this study are currently given in cases of high-risk pregnancies and male idiopathic infertility (Wong et al., 2002; Ebisch et al., 2007) . These intakes exceed the tolerable upper limit of folic acid intake that is known to have no toxicity, which is set at 1000 μg/day (Institute of Medicine (US) Standing Committee on the Scientific Evaluation of Dietary Reference Intakes and its Panel on Folate, 1998). There are a few key differences between our previous study where folic acid supplements of 5 mg/day were shown to affect the sperm epigenome and this study where they did not. First, our previous study included only men with a diagnosis of infertility, whereas men in this study had no history of infertility. It may be that infertile men and men with no history of infertility respond differently to folic acid supplements. However, the second key difference between the studies is likely more important, i.e. the administration of low-level (400 μg/day) versus high-level (5 mg/day) folic acid supplements. It is reassuring that folic acid supplements of 400 μg/day do not affect the sperm epigenome in men with no history of infertility. However, as infertility specialists are currently treating infertile individuals with folic acid supplements to both increase sperm counts and decrease sperm DNA damage, studies to determine a moderate level of folic acid supplementation that does not induce epigenetic defects in sperm are warranted.
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